{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:47:44Z","timestamp":1791560864826,"version":"4.3.4"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Mucormycosis is a deadly fungal infection that mainly affects severely immunocompromised patients. We report herein the case of a previously immunocompetent adult woman who developed invasive cutaneous mucormycosis after severe burn injuries. Interferon-gamma (IFN-\u03b3) treatment was added after failure of conventional treatment and confirmation of a sustained profound immunodepression. The diagnosis was based on a reduced expression of HLA-DR on monocytes (mHLA-DR), NK lymphopenia and a high proportion of immature neutrophils. The immune-related alterations were longitudinally monitored using panels of immune-related biomarkers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Initiation of IFN-\u03b3 was associated with a rapid clinical improvement and a subsequent healing of mucormycosis infection, with no residual fungi at the surgical wound repair. The serial immunological assessment showed sharp improvements of immune parameters: a rapid recovery of mHLA-DR and of transcriptomic markers for T-cell proliferation. The patient survived and was later discharged from the ICU.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The treatment with recombinant IFN-\u03b3 participated to the resolution of a progressively invasive mucormycosis infection, with rapid improvement in immune parameters. In the era of precision medicine in the ICU, availability of comprehensive immune monitoring tools could help guiding management of refractory infections and provide rationale for immune stimulation strategies in these high risk patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.883638","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T11:39:51Z","timestamp":1661168391000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Interferon gamma as an immune modulating adjunct therapy for invasive mucormycosis after severe burn \u2013 A case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Dina M.","family":"Tawfik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dereux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Alexis","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Boibieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Braye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Cazauran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meja","family":"Rabodonirina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Cerrato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Guichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Venet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Monneret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Payen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Lukaszewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Textoris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1055\/s-0039-3401992","article-title":"Mucormycosis","volume":"41","author":"Reid","year":"2020","journal-title":"Semin Respir Crit Care Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-010-0129-9","article-title":"Recent advances in the treatment of mucormycosis","volume":"12","author":"Spellberg","year":"2010","journal-title":"Curr Infect Dis Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/jof4030090","article-title":"Therapy of mucormycosis","volume":"4","author":"Sipsas","year":"2018","journal-title":"J Fungi (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S1473-3099(16)30541-2","article-title":"Nivolumab plus interferon-\u03b3 in the treatment of intractable mucormycosis","volume":"17","author":"Grimaldi","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.165","article-title":"Advances in the understanding and treatment of sepsis-induced immunosuppression","volume":"14","author":"Venet","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw563","article-title":"Detection of circulating mucorales DNA in critically ill burn patients: Preliminary report of a screening strategy for early diagnosis and treatment","volume":"63","author":"Legrand","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2016.08.011","article-title":"Identification of CD177 as the most dysregulated parameter in a microarray study of purified neutrophils from septic shock patients","volume":"178","author":"Demaret","year":"2016","journal-title":"Immunol Lett"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.12.21253466","article-title":"Immune profiling demonstrates a common immune signature of delayed acquired immunodeficiency in patients with various etiologies of severe injury","volume":"50","author":"Venet","year":"2021","journal-title":"Crit Care Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"R287","DOI":"10.1186\/cc13150","article-title":"Decreased HLA-DR antigen-associated invariant chain (CD74) mRNA expression predicts mortality after septic shock","volume":"17","author":"Cazalis","year":"2013","journal-title":"Crit Care"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2016.03.026","article-title":"The multifaceted roles of the invariant chain CD74\u2013more than just a chaperone","volume":"1863","author":"Schroder","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1038\/s41467-019-12013-y","article-title":"In vivo epigenetic editing of Sema6a promoter reverses transcallosal dysconnectivity caused by C11orf46\/Arl14ep risk gene","volume":"10","author":"Peter","year":"2019","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903151","article-title":"IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis","volume":"184","author":"Unsinger","year":"2010","journal-title":"J Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"165974","DOI":"10.1155\/2013\/165974","article-title":"Cytokines in sepsis: potent immunoregulators and potential therapeutic targets\u2013an updated view","volume":"2013","author":"Schulte","year":"2013","journal-title":"Mediators Inflamm"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152388","article-title":"Evaluation of mRNA biomarkers to identify risk of hospital acquired infections in children admitted to paediatric intensive care unit","volume":"11","author":"Peronnet","year":"2016","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3432587","DOI":"10.1155\/2020\/3432587","article-title":"Identification of potential biomarkers and immune features of sepsis using bioinformatics analysis","volume":"2020","author":"Gong","year":"2020","journal-title":"Mediators Inflamm"},{"key":"B16","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1186\/s12879-019-4526-x","article-title":"Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. a case series","volume":"19","author":"Payen","year":"2019","journal-title":"BMC Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41038-017-0089-5","article-title":"Sepsis in the burn patient: a different problem than sepsis in the general population","volume":"5","author":"Greenhalgh","year":"2017","journal-title":"Burns Trauma"},{"key":"B18","doi-asserted-by":"publisher","first-page":"101007","DOI":"10.1016\/j.mycmed.2020.101007","article-title":"Mucormycosis treatment: Recommendations, latest advances, and perspectives","volume":"30","author":"Brunet","year":"2020","journal-title":"J Mycol Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir885","article-title":"Combination therapy for mucormycosis: why, what, and how","author":"Spellberg","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200903-0363OC","article-title":"Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial","volume":"180","author":"Meisel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/1471-2334-14-166","article-title":"Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series","volume":"14","author":"Delsing","year":"2014","journal-title":"BMC Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201204-0645OC","article-title":"Reversal of immunoparalysis in humans in vivo: A double-blind, placebo-controlled, randomized pilot study","volume":"186","author":"Leentjens","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFNgamma: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.580250","article-title":"A longitudinal study of immune cells in severe COVID-19 patients","volume":"11","author":"Payen","year":"2020","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"102146","DOI":"10.1016\/j.dsx.2021.05.019","article-title":"Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India","volume":"15","author":"Singh","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27172","article-title":"Immunostimulation with interferon-gamma in protracted SARS-CoV-2 pneumonia","volume":"93","author":"Lukaszewicz","year":"2021","journal-title":"J Med Virol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-021-06377-3","article-title":"Potential role for interferon gamma in the treatment of recurrent ventilator-acquired pneumonia in patients with COVID-19: A hypothesis","volume":"47","author":"Nguyen","year":"2021","journal-title":"Intensive Care Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa248","article-title":"Immune profiling panel: A proof-of-Concept study of a new multiplex molecular tool to assess the immune status of critically ill patients","volume":"222","author":"Tawfik","year":"2020","journal-title":"J Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.883638\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T11:39:55Z","timestamp":1661168395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.883638\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2022.883638"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.883638","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]},"article-number":"883638"}}